A new sort of Alzheimer's drug shows glimmers of promise
Reported byScience News ↗·Sourced by Goodlede
An experimental drug targeting tau protein lowered tau levels and showed small improvements in memory loss in clinical trial data, offering a new therapeutic approach complementary to recently approved amyloid-targeting drugs.
Early-stage trial results; 'glimmers of promise' reflects limited data so far.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at Science News
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede